Sven Kili

Sven Kili is an advisor at LGC. Sven has over 25 years of experience in the pharmaceutical and biotech industry. Sven has held various leadership positions in companies such as GSK, CCRM, SVEN KILI CONSULTING LTD, UCL, and the BioIndustry Association. In 2015, they were appointed as the VP and Head of Cell & Gene Therapy Development at GSK, where they were responsible for the development of a portfolio of ex-vivo stem cell gene therapies. Sven has also served on the Board of Xintela AB since September 2014.

Sven Kili is a medical doctor who has studied both medicine and surgery. Sven has a degree from the Royal College of Surgeons of England and a degree from Stellenbosch University.